Myriad Genetics Inc MYGN

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

MYGN hizo una división de acciones (split) de 2:1 el 26 de marzo de 2009: cada acción se convirtió en 2. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 24 sept

  Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product Segments

  The global paternity and relationship testing market is expanding beyond traditional paternity testing into broader applications including maternity, grandparent, sibling, and infidelity testing. The market is projected to grow from $1.08 billion in 2025 to $1.45 billion by 2030 at a CAGR of 6.1%. Growth is driven by increased direct-to-consumer genetic testing accessibility, cultural shifts in family definitions, and demand for legally recognized testing. However, the market faces challenges from increased competition, lower pricing, and regulatory complexity across jurisdictions.

  

• GlobeNewswire Inc. 16 sept

  Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial

  Myriad Genetics announced the promotion of Vishal Sikri to Executive Vice President - Commercial effective September 16, 2026, replacing departing Chief Commercial Officer Brian Donnelly. Sikri, who previously served as SVP of Product, brings molecular diagnostics and oncology expertise. The company reaffirmed its full-year 2026 financial guidance.

  

• GlobeNewswire Inc. 7 ago

  MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm

  Law firm Bragar Eagel & Squire is investigating Myriad Genetics for potential securities violations following the company's disappointing Q2 2026 earnings report. Myriad reported revenue of $190.7 million, down 11% year-over-year and significantly below consensus estimates. The company slashed full-year 2026 revenue guidance from $860-$880 million to $770-$790 million and suspended EBITDA guidance, citing reimbursement pressure, collection issues, and weak prenatal performance. This represents a dramatic $90 million midpoint cut just three months after reiterating prior guidance in May 2026.

  

• GlobeNewswire Inc. 5 ago

  MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

  Law firm Kirby McInerney LLP is investigating Myriad Genetics for potential securities fraud following the company's July 30, 2026 earnings report. Myriad reported an 11% year-over-year revenue decline to $190.7 million, reduced full-year guidance, and an $11 million revenue adjustment. Hereditary cancer testing revenue fell 13% despite volume growth, attributed to lower reimbursement and unfavorable estimate changes. Management acknowledged delayed engagement with payers regarding authorization and denial issues. The stock declined 47% to $2.86 on July 31, 2026.

  

• GlobeNewswire Inc. 19 jun

  Ovarian Cancer Diagnostics Market Size to Reach USD 8.08 Billion by 2035 | SNS Insider

  The global ovarian cancer diagnostics market is valued at USD 4.92 billion in 2025 and is projected to reach USD 8.08 billion by 2035, growing at a CAGR of 5.06%. Growth is driven by rising ovarian cancer incidence, increasing adoption of AI-powered imaging, biomarker testing, and precision oncology diagnostics. North America leads with 41.2% market share, while imaging and hospital laboratories dominate their respective segments.